The content on this site is intended for healthcare professionals only
Advances in the treatment of lung cancer
Published: 7 Jun 2010
Views: 9312
Prof Rafael Rosell - University of Barcelona
Prof Rafael Rosell, speaking at the 2010 ELCC conference, talks about the importance of the ELCC 2010 conference and outlines the advances in lung cancer treatment that he has presented at this year's conference.
Watch Prof Rosell's presentation at ESMO 33 on the benefits of customising erlotinib therapy for NSCLC.
Watch Prof Rosell's presentation at ESMO 33 on the benefits of customising erlotinib therapy for NSCLC.
- Categories:
- Lung & pleura
- Targeted molecules
Related Videos
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
5 Jun 2022
Latest in testing and diagnostics in exon 20 NSCLC
Dr Antonio Passaro and Prof Paul Hofman
4 Jun 2022
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year...
Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
10 May 2022
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for rese...
Prof Nicolas Girard - Institut Curie, Paris, France
10 May 2022
Recent advances in the treatment of patients with exon 20 insertion-positive NSC...
Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl
21 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
14 Apr 2022
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari
30 Mar 2022
WCLC 2021: Epidemiology of MET Exon 14 mutations
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinge...
19 Oct 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
11 Oct 2021